" class="no-js "lang="en-US"> ECCMID Archives - Medtech Alert
Saturday, June 21, 2025

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Enrique Neumann, Beckman Coulter Diagnostics, on Automation Solutions

In the video, Enrique Neumann, the Field Marketing Manager of Genomics from Beckman Coulter Diagnostics, […]

Matthew Crowther, Beckman Coulter Diagnostics, on Emerging Resistance

In this video, Matthew Crowther, the Northern Europe Sales Manager at Beckman Coulter Diagnostics, discusses […]

Keegan Nees, IMMY, on Fungal Infection Diagnostics

We caught up with Keegan Nees, a Product Marketing Strategist from IMMY, at ECCMID, who discusses […]

Dwaine Vance, Randox, on Molecular Diagnostics

At ECCMID, we caught up with Dwaine Vance from Randox, who discusses his company’s contribution […]

Michael Corley, BSAC, on Partnerships Within the Antibiotic Community

In the video, Michael Corley, the Head of Policy & Public Affairs at the British […]

Dr. Jacqueline Sneddon, BSAC, on Antibiotics

At the 33rd ECCMID event, we caught up with Dr. Jacqueline Sneddon, the Programmes Manager […]

Nelson Fernandes, CerTest Biotec, on Diagnostic Products

We caught up with Nelson Fernandes, the Managing Director at CerTest Biotec, at 33rd ECCMID […]

Katerina Evangeli, Pro-Lab Diagnostics, on New Diagnostic Products and Technologies

In this interview, Katerina Evangeli, Territory Manager at Pro-Lab Diagnostics, discussed her company’s new Diagnostic […]

MTA's ECCMID 2023 Highlight Reel

The 33rd ECCMID (European Congress of Clinical Microbiology and Infectious Diseases) is a scientific conference […]

ECCMID 2023: Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir Treatment

Shionogi today announced that two late-breaking poster presentations featuring new results from the Phase 3 […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more